Alnylam Pharma (ALNY) Stock Forecast & Price Target

Compare

1,258 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALNY Analyst Ratings

Strong Buy

19 Buy

5 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Alnylam

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$343.14

▲(8.95%Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $343.14 with a high forecast of $500.00 and a low forecast of $245.00. The average price target represents a 8.95% change from the last price of $314.94.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"234":"$234","501":"$501","300.75":"$300.8","367.5":"$367.5","434.25":"$434.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":343.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$343.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$245.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[234,300.75,367.5,434.25,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,322.06,335.7476923076923,349.43538461538463,363.12307692307695,376.8107692307692,390.4984615384615,404.18615384615384,417.87384615384616,431.5615384615385,445.24923076923073,458.9369230769231,472.62461538461537,486.3123076923077,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,322.06,323.6815384615385,325.3030769230769,326.9246153846154,328.54615384615386,330.1676923076923,331.78923076923076,333.41076923076923,335.0323076923077,336.65384615384613,338.2753846153846,339.8969230769231,341.5184615384615,{"y":343.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,322.06,316.1323076923077,310.2046153846154,304.2769230769231,298.34923076923076,292.4215384615385,286.49384615384616,280.56615384615384,274.63846153846157,268.71076923076924,262.7830769230769,256.85538461538465,250.92769230769233,{"y":245,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":243.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$500.00

Average Price Target$343.14

Lowest Price Target$245.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$337

Hold

7.00%

Upside

Reiterated

06/19/25

Alnylam Pharma's overall score reflects a promising growth trajectory with strong technical indicators and strategic corporate actions. However, the high financial leverage and negative earnings impact the valuation, while the positive earnings call sentiment and corporate event developments highlight potential for future improvement.

Tazeen AhmadBank of America Securities

Bank of America Securities

$336→$359

Buy

13.99%

Upside

Reiterated

07/11/25

Alnylam Pharma's Promising Growth and Market Potential Justify Buy Rating

David LebowitzCiti

Citi

$364→$404

Buy

28.28%

Upside

Reiterated

07/10/25

Citi Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Maury RaycroftJefferies

Jefferies

$328→$384

Buy

21.93%

Upside

Reiterated

07/08/25

Alnylam price target raised to $384 from $328 at JefferiesAlnylam price target raised to $384 from $328 at Jefferies

Luca IssiRBC Capital

RBC Capital

$330→$350

Buy

11.13%

Upside

Reiterated

07/07/25

RBC Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Ritu BaralTD Cowen

TD Cowen

$371

Buy

17.80%

Upside

Reiterated

06/30/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Edgewise Therapeutics (NASDAQ: EWTX) and Arcturus Therapeutics (NASDAQ: ARCT)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/30/25

Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma's Amvuttra

Tiago FauthWells Fargo

Wells Fargo

$287→$333

Hold

5.73%

Upside

Reiterated

06/30/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Roche Holding AG (Other OTC: RHHVF)

Joseph StringerNeedham

Needham

$320→$377

Buy

19.71%

Upside

Reiterated

06/26/25

Alnylam Pharma's Promising Outlook: Analyst Joseph Stringer Raises Price Target Amid Optimism for Amvuttra Launch

Kostas BiliourisBMO Capital

BMO Capital

$300→$360

Buy

14.31%

Upside

Reiterated

06/24/25

Alnylam Pharma (ALNY) Gets a Buy from BMO Capital

William PickeringBernstein

Bernstein

$328

Buy

4.15%

Upside

Reiterated

06/19/25

Bernstein Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Dex GenotekAI Firm

AI Firm

$327→$337

Hold

7.00%

Upside

Reiterated

06/19/25

Michael UlzMorgan Stanley

Morgan Stanley

$287

Hold

-8.87%

Downside

Reiterated

06/09/25

Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$400→$500

Buy

58.76%

Upside

Reiterated

06/03/25

Alnylam Pharma's Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook

Gena WangBarclays

Barclays

$329

Buy

4.46%

Upside

Reiterated

05/27/25

Alnylam Pharma (ALNY) Receives a Buy from Barclays

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$337

Hold

7.00%

Upside

Reiterated

06/19/25

Tazeen AhmadBank of America Securities

Bank of America Securities

$336→$359

Buy

13.99%

Upside

Reiterated

07/11/25

Alnylam Pharma's Promising Growth and Market Potential Justify Buy Rating

David LebowitzCiti

Citi

$364→$404

Buy

28.28%

Upside

Reiterated

07/10/25

Citi Keeps Their Buy Rating on Alnylam Pharma (ALNY)

Maury RaycroftJefferies

Jefferies

$328→$384

Buy

21.93%

Upside

Reiterated

07/08/25

Alnylam price target raised to $384 from $328 at JefferiesAlnylam price target raised to $384 from $328 at Jefferies

Luca IssiRBC Capital

RBC Capital

$330→$350

Buy

11.13%

Upside

Reiterated

07/07/25

RBC Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Ritu BaralTD Cowen

TD Cowen

$371

Buy

17.80%

Upside

Reiterated

06/30/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY), Edgewise Therapeutics (NASDAQ: EWTX) and Arcturus Therapeutics (NASDAQ: ARCT)

Jessica FyeJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

06/30/25

Strong Sales Momentum and Growth Potential Drive Buy Rating for Alnylam Pharma's Amvuttra

Tiago FauthWells Fargo

Wells Fargo

$287→$333

Hold

5.73%

Upside

Reiterated

06/30/25

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Roche Holding AG (Other OTC: RHHVF)

Joseph StringerNeedham

Needham

$320→$377

Buy

19.71%

Upside

Reiterated

06/26/25

Alnylam Pharma's Promising Outlook: Analyst Joseph Stringer Raises Price Target Amid Optimism for Amvuttra Launch

Kostas BiliourisBMO Capital

BMO Capital

$300→$360

Buy

14.31%

Upside

Reiterated

06/24/25

Alnylam Pharma (ALNY) Gets a Buy from BMO Capital

William PickeringBernstein

Bernstein

$328

Buy

4.15%

Upside

Reiterated

06/19/25

Bernstein Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

Dex GenotekAI Firm

AI Firm

$327→$337

Hold

7.00%

Upside

Reiterated

06/19/25

Michael UlzMorgan Stanley

Morgan Stanley

$287

Hold

-8.87%

Downside

Reiterated

06/09/25

Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$400→$500

Buy

58.76%

Upside

Reiterated

06/03/25

Alnylam Pharma's Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook

Gena WangBarclays

Barclays

$329

Buy

4.46%

Upside

Reiterated

05/27/25

Alnylam Pharma (ALNY) Receives a Buy from Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

1 Month

xxx

Success Rate

15/26 ratings generated profit

Average Return

+0.78%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +0.78% per trade.

3 Months

xxx

Success Rate

20/30 ratings generated profit

Average Return

+9.58%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.58% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

26/30 ratings generated profit

Average Return

+31.33%

reiterated a buy rating 14 days ago

Copying Ritu Baral's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +31.33% per trade.

2 Years

xxx

Success Rate

22/22 ratings generated profit

Average Return

+47.15%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALNY has received 32 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 343.14.

Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is -$0.60 with a range of -$1.34 to $0.70. The previous quarter’s EPS was -$0.44. ALNY beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 76.47% of the time in the same period. In the last calendar year ALNY has Preformed in-line its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $646.16M with a range of $562.00M to $827.00M. The previous quarter’s sales results were $594.19M. ALNY beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.44% of the time in the same period. In the last calendar year ALNY has Preformed in-line its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?

Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 343.14.

What is ALNY’s upside potential, based on the analysts’ average price target?

Alnylam Pharmaceuticals has 8.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALNY a Buy, Sell or Hold?

Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 5 hold ratings and 0 sell ratings.

What is Alnylam Pharmaceuticals’s price target?

The average price target for Alnylam Pharmaceuticals is 343.14. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $500.00 ,the lowest forecast is $245.00. The average price target represents 8.95% Increase from the current price of $314.94.

What do analysts say about Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of ALNY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alnylam Pharma (ALNY) Stock Forecast & Price Target

ALNY Analyst Ratings

ALNY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alnylam Pharma

ALNY Analyst Recommendation Trends

ALNY Financial Forecast

ALNY Earnings Forecast

ALNY Sales Forecast

ALNY Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts